The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
In my opinion the current board are just puppets. It’s obvious that the Volt chairman is calling the shots as a major shareholder. Perhaps he’s putting Volt ahead of ACP for his own self interests. Who knows. It’s a diabolical situation considering the opportunity just no real execution of strategy. Management need to change and fast. Looking at past performance nothing that AK has been involved in has performed particularly well from a shareholder return point of view so why should ACP be any different.
Also the deal was done with Jason Brewer who is on he board of a multitude of ASX listed companies. I wouldn’t expect this to be something he will devote much of his time to. I would treat this project like it was just given away. Disappointing really.
That’s extremely worrying. Surely the loan came with an agreement that had rights and obligations. If the loan was secured this would have been detailed in the agreement. Kudos to you for keeping management on their toes.
No point quoting Syrah as a company that ACP can become. Syrah have a market cap of 1b for a reason. They are the most advanced and have the best and biggest deposit by far in my opinion. They will dominate global supply before anyone else can.
Nothing new in here although an updated cash balance at June of 394k. we are three months further down the track with drilling ongoing. I wonder how much they have left. Of course there is the additional 200k available from debt on top of this cash balance.